Head and Neck Squamous Cell Carcinoma (HNSCC) Latest Advances

Find the Latest Research About Head and Neck Squamous Cell Carcinoma (HNSCC)

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24652 publications

mTOR inhibition augments antitumor immune effector response by reprogramming the TP53 -mutant, immune-cold HNSCC tumor microenvironment.

mTOR inhibition augments antitumor immune effector response by reprogramming the TP53 -mutant, immune-cold HNSCC tumor microenvironment.

Journal: bioRxiv : the preprint server for biology
Published: June 22, 2026

Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].

Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].

Journal: Oral oncology
Published: June 19, 2026

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.

Journal: JAMA otolaryngology-- head & neck surgery
Published: June 18, 2026

Editorial note: Long non-coding RNA as a potential diagnostic biomarker in head and neck squamous cell carcinoma: A systematic review and meta-analysis.

Editorial note: Long non-coding RNA as a potential diagnostic biomarker in head and neck squamous cell carcinoma: A systematic review and meta-analysis.

Journal: PloS one
Published: June 17, 2026

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 17, 2026

Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).

Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).

Journal: JCO global oncology
Published: June 17, 2026

Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.

Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.

Journal: Immuno-oncology technology
Published: June 15, 2026

High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.

High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026

Curcumin suppresses head and neck squamous cell carcinoma progression via NCOA4-FTH1-mediated ferroptosis.

Curcumin suppresses head and neck squamous cell carcinoma progression via NCOA4-FTH1-mediated ferroptosis.

Journal: Acta biochimica et biophysica Sinica
Published: June 10, 2026

Andrographolide Suppresses Head and Neck Squamous Cell Carcinoma Progression via EGR1-ACSL4 Axis-Mediated Ferroptosis.

Andrographolide Suppresses Head and Neck Squamous Cell Carcinoma Progression via EGR1-ACSL4 Axis-Mediated Ferroptosis.

Journal: The American journal of Chinese medicine
Published: June 08, 2026

A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.

A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.

Journal: Oncotarget
Published: June 06, 2026

Virtual photon-counting micro-CT platform for simulation of head and neck cancer imaging in mice.

Virtual photon-counting micro-CT platform for simulation of head and neck cancer imaging in mice.

Journal: Physics in medicine and biology
Published: June 05, 2026
Showing 1-12 of 24,652

Last Updated: 06/30/2026